

EXHIBIT E

| Claim 1 of U.S. Patent No. 7,145,044 | Accused Process |
|--|---|
| <p>A method of crystallizing reduced coenzyme Q₁₀</p> | <p>Exhibit C states that DuoQuinol/CoQnol is a form of Ubiquinol and produced through a method involving the use of geranygeraniol and ascorbyl palmitate. Uniquinol is another name for reduced coenzyme Q10.</p> |
| <p>which comprises crystallizing the reduced coenzyme Q10 using as a solvent at least one species selected from the group consisting of hydrocarbons, fatty acid esters, ethers or nitriles.</p> | <p>Exhibit D, Reports 2 and 3 show that the CoQnol product containing reduced Q10 is crystallized.</p> <p>The label on a bottle of CoQnol states that the product contains Medium Chain Triglycerides (MCT), MCT oil is a fatty acid ester and a solvent.</p> |

| Claim 13 of U.S. Patent No. 7,145,044 | Accused Process |
|---|--|
| A reduced coenzyme Q ₁₀ crystal. | Exhibit C states that DuoQuinol/CoQnol is a form of Ubiquinol. Ubiquinol is another name for reduced coenzyme Q10. |
| with a reduced coenzyme Q10 / oxidized Q10 weight ratio of not lower than 96/4. | <p>Exhibit D, Reports 2 and 3 show that the CoQnol product containing reduced Q10 is crystallized.</p> <p>Exhibit D, Report 1, Table 1 shows that the reduced Q10 weight ratio was 99.7 in the CoQnol capsule.</p> |

| Claim 1 of U.S. Patent No. 7,829,080 | Accused Product |
|--|---|
| <p>A method for stabilizing reduced coenzyme Q₁₀, which method comprises</p> | <p>Exhibit C states that DuoQuinol/CoQnol is a form of Ubiquinol and produced through a method involving the use of geranygeraniol and ascorbyl palmitate. Any production of reduced coenzyme Q10 (Ubiquinol) must be stabilized to protect the reduced Q10 from oxidation.</p> |
| <p>preparing a reduced coenzyme Q₁₀-containing composition comprising reduced coenzyme Q₁₀ and one or both of (a) and (b):</p> <p>(a) not less than 1.5 wt % to not more than 99 wt % of reduced coenzyme Q₉ relative to reduced coenzyme Q₁₀, and</p> <p>(b) reduced coenzyme Q₁₁,</p> | <p>Exhibit D, Report 1, Table 2 shows that the CoQnol product contains 88 ug of reduced Q11.</p> |

| | |
|--|---|
| wherein not less than 0.01 wt % of reduced coenzyme Q ₁₀ is contained in the composition, and | Exhibit D, Report 1, Table 1 shows that the amount of reduced coenzyme Q10 in the CoQnol capsule is 222.3 mg where the combination composition of Q10 and reduced Q10 was 223 mg. |
| wherein the proportion of reduced coenzyme Q ₁₀ relative to the total amount of coenzyme Q ₁₀ is not less than 90 wt %, thereby stabilizing reduced coenzyme Q ₁₀ . | Exhibit D, Report 1, Table 1 shows that the amount of reduced coenzyme Q10 in the CoQnol capsule is 99.7 %. |

| Claim 5 of U.S. Patent No. 7,829,080 | Accused Product |
|--|---|
| <p>A reduced coenzyme Q₁₀-containing composition comprising reduced coenzyme Q₁₀ and one or both of (a) and (b):</p> <p>a) not less than 1.5 wt % to not more than 99 wt % of reduced coenzyme Q₉ relative to reduced coenzyme Q₁₀, and</p> <p>(b) reduced coenzyme Q₁₁</p> | <p>Exhibit C states that DuoQuinol/CoQnol is a form of Ubiquinol which is another name for reduced coenzyme Q10.</p> <p>Exhibit D, Report 1, Table 2 shows that the CoQnol product contains 88 ug of reduced Q11.</p> |
| <p>wherein not less than 0.01 wt % of reduced coenzyme Q₁₀ is contained in the composition, and</p> | <p>Exhibit D, Report 1, Table 1 shows that the amount of reduced coenzyme Q10 in the CoQnol capsule is 222.3 mg where the combination composition of Q10 and reduced Q10 was 223 mg.</p> |
| <p>wherein the proportion of reduced coenzyme Q₁₀ relative to the total amount of coenzyme Q₁₀ is not less than 90 wt %.</p> | <p>Exhibit D, Report 1, Table 1 shows that the amount of reduced coenzyme Q10 in the CoQnol capsule is 99.7 %.</p> |

| Claim 15 of U.S. Patent No. 7,829,080 | Accused Product |
|--|--|
| <p>A method for producing a reduced coenzyme Q₁₀-containing composition, which method comprises</p> | <p>Exhibit C states that DuoQuinol/CoQnol is a form of Ubiquinol (reduced coenzyme Q10) and produced through a method involving the use of geranygeraniol and ascorbyl palmitate.</p> |
| <p>providing a composition comprising oxidized coenzyme Q₁₀ with one or both of oxidized coenzyme Q₉ and oxidized coenzyme Q₁₁,</p> | <p>Exhibit D, Report 1, Table 1 shows that the CoQnol product includes oxidized Q10 and Table 2 shows that the CoQnol product includes Q11.</p> |
| <p>and then reducing oxidized coenzyme Q₁₀ and reducing one or both of oxidized coenzyme Q₉ and oxidized coenzyme Q₁₁ to prepare the reduced coenzyme Q₁₀-containing composition,</p> | <p>The accused method reduces oxidized coenzyme Q₁₀, to produce reduced coenzyme Q10 and, during that reaction, the coenzyme Q11 is also reduced.</p> |
| <p>wherein the composition comprises reduced coenzyme Q₁₀ and one or both of (a) not less than 1.5 wt % to not more than 99 wt % of reduced coenzyme Q₉ relative to reduced coenzyme Q₁₀ and (b) reduced coenzyme Q₁₁,</p> | <p>Exhibit D, Report 1, Table 2 shows that the CoQnol product contains 88 ug of Q11.</p> |
| <p>wherein not less than 0.01 wt % of reduced coenzyme Q₁₀ is contained in the composition, and</p> | <p>Exhibit D, Report 1, Table 1 shows that the amount of reduced coenzyme Q10 in the CoQnol capsule is 222.3 mg where the combination composition of Q10 and reduced Q10 was 223 mg.</p> |

| | |
|---|---|
| | |
| wherein the proportion of reduced coenzyme Q ₁₀ relative to the total amount of coenzyme Q ₁₀ is not less than 90 wt %. | Exhibit D, Report 1, Table 1 shows that the amount of reduced coenzyme Q10 in the CoQnol capsule is 99.7 %. |